OncoMatch/Clinical Trials/NCT03196414
Study of T Cells Targeting CD138/BCMA/CD19/More Antigens (CART-138/BCMA/19/More) for Chemotherapy Refractory and Relapsed Multiple Myeloma
Is NCT03196414 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CART-138/BCMA/19/more for multiple myeloma.
Treatment: CART-138/BCMA/19/more — Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells. Genetically engineered lymphocyte (CART) therapy has showed good safety and efficacy in treatment of lymphoma and acute lymphoblastic leukemia. Researchers want to see if this helps people with multiple myeloma.To test the safety and efficacy of giving targeting CD138 or B-cell maturation antigen or CD19 or more antigens T cells in treating patients with multiple myeloma that is refractory to further chemotherapy or relapsed(after stem cell transplantation or intensive chemotherapy).
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: SDC1 antigen positive
CD138 or BCMA antigen positive multiple myeloma
Required: BCMA (TNFRSF17) antigen positive
CD138 or BCMA antigen positive multiple myeloma
Prior therapy
Must have received: autologous or allogeneic stem cell transplant — relapsed after prior autologous or allogenic SCT
Relapsed after prior autologous or allogenic SCT
Cannot have received: gene therapy
Previously treatment with any gene therapy products
Lab requirements
Blood counts
blood coagulation function: pt and aptt < 2x normal
Kidney function
creatinine < 2.0 mg/dl
Liver function
alt/ast < 3x normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify